Highlights from Day 2 of the ESC 2021 congress – ENVISAGE-TAVI AF

The ENVISAGE-TAVI AF trial demonstrated that Edoxaban’s non-inferiority to warfarin with regards to myocardial infarction (MI), ischaemic stroke, systemic thromboembolism, and valve thrombosis, in participants…

View More Highlights from Day 2 of the ESC 2021 congress – ENVISAGE-TAVI AF
Figure 1: Taken from Chen et al (2020). Incidence of clinically driven target lesion revascularisation (TLR), target vessel myocardial infarction (TVMI), and target lesion failure (TLF). The table shows the hazard ratio and 95% confidence interval for TLR, TVMI, and TLF in the two-stent vs provisional stent group.

In case you missed it: a summary of the BCS ’21 top 10 trials (Part I)

One of the most popular sessions every year, an excellent variety of trials were presented at the 2021 BCS Annual Conference. For those that were unable to attend, or for the sake of refreshing one’s memory, the following is a summary of all the trials presented…

View More In case you missed it: a summary of the BCS ’21 top 10 trials (Part I)